NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

全球真性紅血球增生症(PV)治療市場:各疾病類型,各類藥物,各給藥途徑,各流通管道,各地區的市場規模,佔有率,展望及機會分析(2021年∼2028年)

Polycythemia Vera Therapeutics Market, by Disease Type, by Drug Class, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

出版商 Coherent Market Insights 商品編碼 1021669
出版日期 內容資訊 英文 218 Pages
商品交期: 2-3個工作天內
價格
全球真性紅血球增生症(PV)治療市場:各疾病類型,各類藥物,各給藥途徑,各流通管道,各地區的市場規模,佔有率,展望及機會分析(2021年∼2028年) Polycythemia Vera Therapeutics Market, by Disease Type, by Drug Class, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028
出版日期: 2021年07月22日內容資訊: 英文 218 Pages
簡介

真性紅血球增多症是一種血液疾病,身體會產生過多的紅血球。這些額外的紅血球使血液比正常情況更濃。變稠的血液流動較慢,可能會在體內凝結。紅血球將氧氣輸送到全身的器官和組織。如果血液流動太慢或凝結,細胞就無法輸送足夠的氧氣。這種情況會導致嚴重的併發症,包括心臟病發作、中風和心力衰竭。

本報告提供全球真性紅血球增生症(PV)治療市場相關調查分析,市場概要,市場規模與預測,各市場區隔的市場分析,各地區的市場分析,競爭情形等相關的系統性資訊。

目錄

第1章 調查目的、前提條件

第2章 市場展望

  • 報告的說明
    • 市場定義和範圍
  • 摘要整理
    • 市場明細:各疾病類型
    • 市場明細:各醫藥品分類
    • 市場明細:各給藥途徑
    • 市場明細:各流通管道
    • 市場明細:各地區
  • Coherent Opportunity Map(COM)

第3章 市場動態,法規,及趨勢分析

  • 市場動態
    • 成長要素
    • 阻礙因素
    • 市場機會
  • 影響分析
  • 開發平台分析
  • PEST分析
  • 法規方案
  • 市場趨勢
  • 主要的焦點
  • 償付方案
  • 合併、收購

第4章 全球真性紅血球增生症(PV)治療市場-新型冠狀病毒感染疾病(Covid-19)大流行的影響

  • 經濟影響
  • 臨床試驗和醫藥品開發的影響
  • 政府舉措

第5章 全球真性紅血球增生症(PV)治療市場:各疾病類型,2017年∼2028年,(百萬美元)

  • 簡介
  • 原發性真性紅血球增生症
  • 續發性真性紅血球增生症

第6章 全球真性紅血球增生症(PV)治療市場:各醫藥品分類,2017年∼2028年,(百萬美元)

  • 簡介
  • 代謝拮抗劑
  • 激化酵素抑制劑
  • Alpha干擾素
  • 選擇性血清素回收抑制劑
  • 其他

第7章 全球真性紅血球增生症(PV)治療市場:各給藥途徑,2017年∼2028年,(百萬美元)

  • 簡介
  • 口服
  • 靜脈內
  • 肌肉內
  • 皮下

第8章 全球真性紅血球增生症(PV)治療市場:各流通管道,2017年∼2028年,(百萬美元)

  • 簡介
  • 醫院藥局
  • 零售藥局
  • 線上藥局

第9章 全球真性紅血球增生症(PV)治療市場:各地區,2017年∼2028年,(百萬美元)

  • 簡介
  • 北美
  • 南美
  • 歐洲
  • 亞太地區
  • 中東
  • 非洲

第10章 競爭情形

  • 熱圖分析
  • 市場佔有率分析
    • Pfizer Inc.
    • Galena Biopharma
    • Bristol-Myers Squibb Company
    • Novartis AG
    • Eli Lilly and Company
    • PharmaEssentia Corporation
    • Bayer AG
    • Mylan NV
    • Teva Pharmaceuticals Industries Ltd
    • GlaxosmithKline plc
    • ANP Technologies, INC.
    • F. Hoffmann-La Roche Ltd.
    • Gilead Sciences, Inc
    • Karus Therapeutics Limited
    • Miragen Therapeutics, Inc.
  • 分析師的見解

第11章 Section

目錄

Polycythemia vera is a blood disorder in which the body creates too many red blood cells. These extra red cells make blood thicker than normal. The thickened blood flows slower and may clot within body. Red blood cells carry oxygen to organs and tissues throughout the body. If the blood moves too slowly or clots, the cells cannot deliver enough oxygen. This situation can cause serious complications including heart attack, stroke, and heart failure. There are two types of polycythemia vera, which include primary polycythemia vera and secondary polycythemia vera. Polycythemia vera gets worse with time if remain undiagnosed and can be life-threatening. Polycythemia vera can be treatable but is not curable. Polycythemia vera treatment may include phlebotomy and drug therapy. Phlebotomy involves the removal of blood from the body. Drug therapy involves the use of Hydroxyurea and Interferon-alfa. Patients who do not respond to hydroxyurea are treated with ruxolitinib (jakafi) or busulfan. At times a low dose of aspirin, allopurinol and antihistamines are also preferred for polycythemia vera treatment. Givinostat is an emerging drug in global polycythemia vera treatment market.

Market Dynamics

The increasing incidence of polycythemia vera, rising research and development activities for the development of novel therapeutics for the treatment of polycythemia vera, and increasing adoption of inorganic growth strategies such as acquisitions and collaborations by key players operating in the market, are the major factors that are expected to drive growth of the global polycythemia vera therapeutics market over the forecast period.

For instance, according to the National Organization for Rare Disorders, polycythemia vera affects slightly more men than women and the disorder is estimated to affect around 44 to 57 per 100,000 people in the U.S. each year It occurs most often in individuals over 60 years old, but can affect individuals of any age. It is extremely rare in individuals under the age of 20.

Key features of the study:

  • This report provides in-depth analysis of the global polycythemia vera therapeutics market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021-2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global polycythemia vera therapeutics market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Pfizer Inc, Galena Biopharma, Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, PharmaEssentia Corporation, Bayer AG, Mylan N.V., Teva Pharmaceuticals Industries Ltd, GlaxosmithKline plc, ANP Technologies, INC., F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc, Karus Therapeutics Limited, and Miragen Therapeutics, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global polycythemia vera therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global polycythemia vera therapeutics market

Detailed Segmentation:

  • Global Polycythemia Vera Therapeutics Market, By Disease Type:
    • Primary Polycythemia Vera
    • Secondary Polycythemia Vera
  • Global Polycythemia Vera Therapeutics Market, By Drug Class:
    • Antimetabolite
    • Kinase Inhibitors
    • Alpha Interferon
    • Selective Serotonin Reuptake Inhibitors
    • Others
  • Global Polycythemia Vera Therapeutics Market, By Route of Administration:
    • Oral
    • Intravenous
    • Intramuscular
    • Subcutaneous
  • Global Polycythemia Vera Therapeutics Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Polycythemia Vera Therapeutics Market, By Region:
    • North America
      • By Disease Type
      • Primary Polycythemia Vera
      • Secondary Polycythemia Vera
      • By Drug Class
      • Antimetabolite
      • Kinase Inhibitors
      • Alpha Interferon
      • Selective Serotonin Reuptake Inhibitors
      • Others
      • By Route of Administration
      • Oral
      • Intravenous
      • Intramuscular
      • Subcutaneous
      • By Distribution Channel
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country
      • U.S.
      • Canada
    • Latin America
      • By Disease Type
      • Primary Polycythemia Vera
      • Secondary Polycythemia Vera
      • By Drug Class
      • Antimetabolite
      • Kinase Inhibitors
      • Alpha Interferon
      • Selective Serotonin Reuptake Inhibitors
      • Others
      • By Route of Administration
      • Oral
      • Intravenous
      • Intramuscular
      • Subcutaneous
      • By Distribution Channel
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Europe
      • By Disease Type
      • Primary Polycythemia Vera
      • Secondary Polycythemia Vera
      • By Drug Class
      • Antimetabolite
      • Kinase Inhibitors
      • Alpha Interferon
      • Selective Serotonin Reuptake Inhibitors
      • Others
      • By Route of Administration
      • Oral
      • Intravenous
      • Intramuscular
      • Subcutaneous
      • By Distribution Channel
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
    • Asia Pacific
      • By Disease Type
      • Primary Polycythemia Vera
      • Secondary Polycythemia Vera
      • By Drug Class
      • Antimetabolite
      • Kinase Inhibitors
      • Alpha Interferon
      • Selective Serotonin Reuptake Inhibitors
      • Others
      • By Route of Administration
      • Oral
      • Intravenous
      • Intramuscular
      • Subcutaneous
      • By Distribution Channel
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • By Disease Type
      • Primary Polycythemia Vera
      • Secondary Polycythemia Vera
      • By Drug Class
      • Antimetabolite
      • Kinase Inhibitors
      • Alpha Interferon
      • Selective Serotonin Reuptake Inhibitors
      • Others
      • By Route of Administration
      • Oral
      • Intravenous
      • Intramuscular
      • Subcutaneous
      • By Distribution Channel
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country
      • GCC
      • Israel
      • Rest of Middle East
    • Africa
      • By Disease Type
      • Primary Polycythemia Vera
      • Secondary Polycythemia Vera
      • By Drug Class
      • Antimetabolite
      • Kinase Inhibitors
      • Alpha Interferon
      • Selective Serotonin Reuptake Inhibitors
      • Others
      • By Route of Administration
      • Oral
      • Intravenous
      • Intramuscular
      • Subcutaneous
      • By Distribution Channel
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country/Region
      • South Africa
      • Central Africa
      • North Africa
  • Company Profiles
    • Pfizer Inc *
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Galena Biopharma
    • Bristol-Myers Squibb Company
    • Novartis AG
    • Eli Lilly and Company
    • PharmaEssentia Corporation
    • Bayer AG
    • Mylan N.V.
    • Teva Pharmaceuticals Industries Ltd
    • GlaxosmithKline plc
    • ANP Technologies, INC.
    • F. Hoffmann-La Roche Ltd.
    • Gilead Sciences, Inc
    • Karus Therapeutics Limited
    • Miragen Therapeutics, Inc.

*marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Disease Type
    • Market Snippet, By Drug Class
    • Market Snippet, By Route of Administration
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Pipeline Analysis
  • PEST Analysis
  • Regulatory Scenario
  • Market Trends
  • Key Highlights
  • Reimbursement Scenario
  • Mergers & Acquisitions

4. Global Polycythemia Vera Therapeutics Market - Impact of Coronavirus (Covid-19) Pandemic

  • Economic Impact
  • Impact on Clinical Trials and Drug Development
  • Government Initiatives

5. Global Polycythemia Vera Therapeutics Market, By Disease Type, 2017 - 2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2021 and 2028 (%)
    • Y-o-Y Growth Analysis, 2018 - 2028
    • Segment Trends
  • Primary Polycythemia Vera
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Secondary Polycythemia Vera
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

6. Global Polycythemia Vera Therapeutics Market, By Drug Class, 2017 - 2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2021 and 2028 (%)
    • Y-o-Y Growth Analysis, 2018 - 2028
    • Segment Trends
  • Antimetabolite
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Kinase Inhibitors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Alpha Interferon
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Selective Serotonin Reuptake Inhibitors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

7. Global Polycythemia Vera Therapeutics Market, By Route of Administration, 2017 - 2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2021 and 2028 (%)
    • Y-o-Y Growth Analysis, 2018 - 2028
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Intravenous
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Intramascular
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Subcutaneous
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

8. Global Polycythemia Vera Therapeutics Market, By Distribution Channel, 2017 - 2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2021 and 2028 (%)
    • Y-o-Y Growth Analysis, 2018 - 2028
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

9. Global Polycythemia Vera Therapeutics Market, By Region, 2017 - 2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, By Region, 2021 and 2028 (%)
    • Y-o-Y Growth Analysis, For Regions, 2018-2028
  • North America
    • Market Size and Forecast, By Disease Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Route of Administration, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
    • U.S.
    • Canada
  • Latin America
    • Market Size and Forecast, By Disease Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Route of Administration, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Market Size and Forecast, By Disease Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Route of Administration, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Disease Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Route of Administration, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • Market Size and Forecast, By Disease Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Route of Administration, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Disease Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Route of Administration, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Region/Country, 2017 - 2028, (US$ Mn)
    • South Africa
    • Central Africa
    • North Africa

10. Competitive Landscape

  • Heat Map Analysis
  • Market Share Analysis
    • Pfizer Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Galena Biopharma
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Bristol-Myers Squibb Company
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Novartis AG
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Eli Lilly and Company
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • PharmaEssentia Corporation
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Bayer AG
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Mylan N.V.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Teva Pharmaceuticals Industries Ltd
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • GlaxosmithKline plc
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • ANP Technologies, INC.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • F. Hoffmann-La Roche Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Gilead Sciences, Inc
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Karus Therapeutics Limited
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Miragen Therapeutics, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
  • Analyst Views

11. Section

  • References
  • Research Methodology
  • About us and Sales Contact